OpenAI unveils GPT-Rosalind to accelerate drug discovery for pharma giants
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
he innovation could pave the way for early and low-cost screening of smoking exposure and second-hand smoke biomarkers
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
The initiative will be led by David Baker, 2024 Nobel Prize winner in Chemistry, IPD director, professor of biochemistry, and HHMI Investigator at the University of Washington
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
Subscribe To Our Newsletter & Stay Updated